A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
dc.contributor.author | Jonker, D J | |
dc.contributor.author | Rosen, L S | |
dc.contributor.author | Sawyer, M B | |
dc.contributor.author | de Braud, F | |
dc.contributor.author | Wilding, G | |
dc.contributor.author | Sweeney, C J | |
dc.contributor.author | Jayson, Gordon C | |
dc.contributor.author | McArthur, G A | |
dc.contributor.author | Rustin, G | |
dc.contributor.author | Goss, G | |
dc.contributor.author | Kantor, J | |
dc.contributor.author | Velasquez, L | |
dc.contributor.author | Syed, S | |
dc.contributor.author | Mokliatchouk, O | |
dc.contributor.author | Feltquate, D M | |
dc.contributor.author | Kollia, G | |
dc.contributor.author | Nuyten, D S A | |
dc.contributor.author | Galbraith, S | |
dc.date.accessioned | 2012-06-27T09:11:56Z | |
dc.date.available | 2012-06-27T09:11:56Z | |
dc.date.issued | 2011-06 | |
dc.identifier.citation | A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. 2011, 22 (6):1413-9 Ann Oncol | en_GB |
dc.identifier.issn | 1569-8041 | |
dc.identifier.pmid | 21131369 | |
dc.identifier.doi | 10.1093/annonc/mdq599 | |
dc.identifier.uri | http://hdl.handle.net/10541/230943 | |
dc.description.abstract | This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMO | en_GB |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Alanine | |
dc.subject.mesh | Angiogenesis Inhibitors | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Dose-Response Relationship, Drug | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Maximum Tolerated Dose | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Neoplasm Metastasis | |
dc.subject.mesh | Neoplasms | |
dc.subject.mesh | Neovascularization, Pathologic | |
dc.subject.mesh | Receptors, Fibroblast Growth Factor | |
dc.subject.mesh | Receptors, Vascular Endothelial Growth Factor | |
dc.subject.mesh | Triazines | |
dc.title | A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. | en |
dc.type | Article | en |
dc.contributor.department | Division of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Canada. | en_GB |
dc.identifier.journal | Annals of Oncology | en_GB |
html.description.abstract | This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors. |
This item appears in the following Collection(s)
-
All Christie Publications
-
Medical Oncology
Medical Oncology